1.

Functional impairments for outcomes in a randomized trial of unruptured brain AVMs

1.

Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a...

1.

Life satisfaction two-years after stroke onset: the effects of gender, occupational status, memory function and quality of life among stroke patients (Newsqol) and their family car...

1.

Harmony within stroke patient-caregiver pairs concerning psychological and social repercussions, two years post-stroke in Luxembourg and Portugal.

1.

Iron Overload in Polytransfused Patients without Heart Failure is Associated with Subclinical Alterations of Systolic Left Ventricular Function using Cardiovascular Magnetic Resona...

2.

Iron Overload in Polytransfused Patients without Heart Failure is Associated with Subclinical Alterations of Systolic Left Ventricular Function using Cardiovascular Magnetic Resona...

3.

Iron Overload in Polytransfused Patients without Heart Failure is Associated with Subclinical Alterations of Systolic Left Ventricular Function using Cardiovascular Magnetic Resona...

1.

Computed Tomography Perfusion Derived Blood-Brain Barrier Permeability Does Not Yet Improve Prediction of Hemorrhagic Transformation

1.

Two years post-stroke, predictors of survivors’ life satisfaction: common associations between Luxembourg and Portugal.

1.

Association of Kidney Disease Measures With Ischemic Versus Hemorrhagic Strokes

1.

Life satisfaction of two-year post-stroke survivors: effects of socioeconomic factors, motor impairment, Newcastle Stroke-specific Quality of Life leasure and World health Organiza...

1.

Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients.

2.

Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients.

3.

Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients.